Envestnet Portfolio Solutions Inc. cut its stake in GSK plc (NYSE:GSK - Free Report) by 13.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,017 shares of the pharmaceutical company's stock after selling 7,125 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in GSK were worth $1,522,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Sunbelt Securities Inc. increased its stake in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock worth $29,000 after acquiring an additional 302 shares during the last quarter. Indiana Trust & Investment Management Co grew its holdings in shares of GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust acquired a new stake in GSK during the fourth quarter worth about $26,000. ST Germain D J Co. Inc. raised its stake in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 522 shares during the period. Finally, Sierra Ocean LLC acquired a new position in GSK in the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 15.74% of the company's stock.
Analyst Upgrades and Downgrades
GSK has been the topic of several analyst reports. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 7th. Morgan Stanley initiated coverage on GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $43.25.
Check Out Our Latest Stock Analysis on GSK
GSK Trading Down 0.8 %
GSK traded down $0.30 during mid-day trading on Wednesday, hitting $38.28. 4,915,788 shares of the stock were exchanged, compared to its average volume of 4,354,700. The firm's fifty day moving average is $36.90 and its two-hundred day moving average is $36.80. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.93. The company has a market cap of $79.24 billion, a PE ratio of 24.08, a PEG ratio of 1.12 and a beta of 0.58. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12.
GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Equities analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.
GSK Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.11%. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio (DPR) is currently 98.74%.
GSK Company Profile
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Articles
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
